Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRO 1286

Next Previous
Drug Profile

PRO 1286

Alternative Names: GEN 1286; PRO-1286

Latest Information Update: 27 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProfoundBio
  • Developer Genmab
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 12 Mar 2026 Genmab terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in the USA (Parenteral) due to the company has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development (NCT06685068)
  • 14 Nov 2024 Genmab plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (Parenteral) in November 2024 (NCT06685068)
  • 13 Nov 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in USA (Parenteral) (NCT06685068)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top